The intestinal microbiota as a predictor for antidepressant treatment outcome in geriatric depression: a prospective pilot study.

OBJECTIVES

(1) To investigate if gut microbiota can be a predictor of remission in geriatric depression and to identify features of the gut microbiota that is associated with remission. (2) To determine if changes in gut microbiota occur with remission in geriatric depression.

DESIGN

Secondary analysis of a parent randomized placebo-controlled trial (NCT02466958).

SETTING

Los Angeles, CA, USA (2016-2018).

PARTICIPANTS

Seventeen subjects with major depressive disorder, over 60 years of age, 41.2% female.

INTERVENTION

Levomilacipran (LVM) or placebo.

MEASUREMENTS

Remission was defined by Hamilton Depression Rating Scale score of 6 or less at 12 weeks. 16S-ribosomal RNA sequencing based fecal microbiota composition and diversity were measured at baseline and 12 weeks. Differences in fecal microbiota were evaluated between remitters and non-remitters as well as between baseline and post-treatment samples. LVM and placebo groups were combined in all the analyses.

RESULTS

Baseline microbiota showed no community level α-diversity or β-diversity differences between remitters and non-remitters. At the individual taxa level, a random forest classifier created with nine genera from the baseline microbiota was highly accurate in predicting remission (AUC = .857). Of these, baseline enrichment of Faecalibacterium, Agathobacter and Roseburia relative to a reference frame was associated with treatment outcome of remission. Differential abundance analysis revealed significant genus level changes from baseline to post-treatment in remitters, but not in non-remitters.

CONCLUSIONS

This is the first study demonstrating fecal microbiota as a potential predictor of treatment response in geriatric depression. Our findings need to be confirmed in larger prospective studies.